Welcome to LookChem.com Sign In|Join Free
  • or
(3-(4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)-azetidin-1-yl)(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl)methanone is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1254035-86-3

Post Buying Request

1254035-86-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1254035-86-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1254035-86-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,4,0,3 and 5 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1254035-86:
(9*1)+(8*2)+(7*5)+(6*4)+(5*0)+(4*3)+(3*5)+(2*8)+(1*6)=133
133 % 10 = 3
So 1254035-86-3 is a valid CAS Registry Number.

1254035-86-3Downstream Products

1254035-86-3Relevant academic research and scientific papers

Hip to Be Square: Oxetanes as Design Elements to Alter Metabolic Pathways

Toselli, Francesca,Fredenwall, Marlene,Svensson, Peder,Li, Xue-Qing,Johansson, Anders,Weidolf, Lars,Hayes, Martin A.

, p. 7383 - 7399 (2019/08/20)

Oxetane-containing ring systems are increasingly used in medicinal chemistry programs to modulate druglike properties. We have shown previously that oxetanes are hydrolyzed to diols by human microsomal epoxide hydrolase (mEH). Mapping the enzymes that contribute to drug metabolism is important since an exaggerated dependence on one specific isoenzyme increases the risk of drug-drug interactions with co-administered drugs. Herein, we illustrate that mEH-catalyzed hydrolysis is an important metabolic pathway for a set of more structurally diverse oxetanes and the degree of hydrolysis is modulated by minor structural modifications. A homology model based on the Bombyx mori EH crystal structure was used to rationalize substrate binding. This study shows that oxetanes can be used as drug design elements for directing metabolic clearance via mEH, thus potentially decreasing the dependence on cytochromes P450. Metabolism by mEH should be assessed early in the design process to understand the complete metabolic fate of oxetane-containing compounds, and further study is required to allow accurate pharmacokinetic predictions of its substrates.

THERAPEUTIC AGENTS 713

-

Page/Page column 46, (2010/11/17)

Disclosed herein are compounds of Formula (I) in which R1, R2, R3, R4, R5, A, X, Y are as described in the specification, their use in pharmaceutical compositions and in methods of treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1254035-86-3